Codiak licenses key exosome technology from MD Anderson
Codiak BioSciences Inc. licensed rights to exosome-based technology for therapeutic and diagnostic uses from the University of Texas's...
Tech Transfer Deals, December 2015
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly review of licensing agreements between companies and universities or other research institutions in the In Vitro Diagnostics, Medical Device, and Pharmaceutical sectors. This month’s column covers deals announced October through November 2015.
More from Deals
• By
Scrip discusses the latest M&A activity and trends with CEO Shawn Titcomb of Allele Capital and Cheryl Reicin, a partner focused on international life sciences activity at Mintz.
• By
The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.
• By
A deal last year with Sanofi relieved Novavax of commercial costs for the COVID-19 vaccine Nuvaxovid, allowing the company to focus on R&D and finding partners for its other vaccines.
• By
The Austrian firm is delisting from the NASDAQ and closing down.
More from Business
• By
The drugmaker plans to build a large manufacturing center in Virginia as the centerpiece of an effort to invest $50bn in the US by 2030.
• By
FDA issued a complete response letter to Replimune’s BLA for a novel oncolytic immunotherapy for melanoma in a surprise to management and investors.
• By
With drug sector indexes underperforming the broad market in the first half of 2025, investors may have been anticipating tariff-related and other headwinds. But impending loss of exclusivity on key products may be provoking more anxiety at this point.